Status:
COMPLETED
Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial
Lead Sponsor:
Imperial College London
Conditions:
HTLV-I-associated Myelopathy
Eligibility:
All Genders
16-75 years
Phase:
PHASE2
PHASE3
Brief Summary
To determine whether the use of two antiviral agents in combination will be better than placebo in the treatment of an inflammatory sidease of the spinal cord caused by HTLV-I
Detailed Description
Randomised, double-blind, placebo-controlled two centre study of zidvoudine plus lamivudine in HAM/TSP 24 patients randomised 1:1 2-4 week lead-in 6 months randomised phase followed by 6 months open-l...
Eligibility Criteria
Inclusion
- HTLV-I-associated myelopathy
Exclusion
- prior exposure to zidovudine or lamivudine on disease modifying therapy
- under age 16
Key Trial Info
Start Date :
November 8 1999
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 30 2002
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00272480
Start Date
November 8 1999
End Date
July 30 2002
Last Update
August 25 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Imperial College
London, United Kingdom, W2 1PG